- NervGen Pharma Corp. (NGEN) has established an Alzheimer’s Disease Scientific Advisory Board
- The biotech company has appointed four world-class scientists and clinical researchers in Alzheimer’s disease
- The advisory board will work closely with NervGen as the company plans its upcoming preclinical studies, clinical trials and in the analyses of the results from these studies
- NervGen President and CEO Paul Brenna said establishing an advisory board focusing on Alzheimer’s disease was an extremely important step forward for the company
- NervGen Pharma Corp. is down 5.08 per cent to C$2.43 per share
NervGen Pharma Corp. (NGEN) has established an Alzheimer’s Disease Scientific Advisory Board.
The biotech company has appointed four world-class scientists and clinical researchers in Alzheimer’s disease; Jeffrey Cummings, MD, ScD, George Perry, PhD, Henrik Zetterberg, MD, PhD and Bruce Lamb, PhD.
The advisory board will work closely with NervGen as the company plans its upcoming preclinical studies, clinical trials and in the analyses of the results from these studies.
NervGen President and CEO Paul Brenna said establishing an advisory board focusing on Alzheimer’s disease was an extremely important step forward for the company.
“Their expertise in Alzheimer’s disease preclinical studies, biomarkers and clinical studies will be invaluable as we plan our future Alzheimer’s disease program for NVG-291 in parallel with our upcoming Phase 1 study in healthy volunteers.”
Dr. Perry said he’s excited about the potential of NVG-291.
“The technology has a unique pharmacological profile, which is very different from other products in preclinical and clinical development in that it focuses on restoring function.”
NervGen is developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer’s disease. NervGen’s platform technology targets protein tyrosine phosphatase sigma, a neural receptor that impedes nerve repair.
NervGen Pharma Corp. is down 5.08 per cent to C$2.43 per share at 1:11pm EST.